Immune Checkpoint Approaches in AML and MDS: A Next Frontier?
March 7th 2017The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.